Format
Sort by
Items per page

Send to

Choose Destination

Best matches for tazarotene/AE:

Pharmacokinetics of tazarotene and acitretin in psoriasis. Heath MS et al. Expert Opin Drug Metab Toxicol. (2018)

Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy Tanghetti E et al. J Drugs Dermatol. (2018)

Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Rademaker M et al. Australas J Dermatol. (2018)

Search results

Items: 1 to 20 of 179

1.

Expanded table: some drugs for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 17;61(1574):e96-e103. No abstract available.

PMID:
31381545
2.

Drugs for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 17;61(1574):89-96. No abstract available.

PMID:
31381544
3.

Risankizumab (Skyrizi) for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jun 3;61(1573):81-83. No abstract available.

PMID:
31170118
4.

Quantification and In Silico Toxicity Assessment of Tazarotene and its Impurities for a Quality and Safe Drug Product Development.

Nagulakonda NNM, Ananthula RS, Krishnamurthy T, Rao MRP, Rao GN.

J Chromatogr Sci. 2019 Aug 1;57(7):625-635. doi: 10.1093/chromsci/bmz037.

PMID:
31037297
5.

Tildrakizumab (Ilumya) - another IL-23 antagonist for psoriasis.

[No authors listed]

Med Lett Drugs Ther. 2019 Jan 14;60(1563):4-6. No abstract available.

PMID:
30681661
6.
7.

Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy

Tanghetti E, Lebwohl M, Stein Gold L.

J Drugs Dermatol. 2018 Dec 1;17(12):1280-1287. Review.

PMID:
30586259
8.

Regulation of Chemerin and CMKLR1 Expression by Nutritional Status, Postnatal Development, and Gender.

Sanchez-Rebordelo E, Cunarro J, Perez-Sieira S, Seoane LM, Diéguez C, Nogueiras R, Tovar S.

Int J Mol Sci. 2018 Sep 25;19(10). pii: E2905. doi: 10.3390/ijms19102905.

9.

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2019 Jan;80(1):282-285. doi: 10.1016/j.jaad.2018.09.002. Epub 2018 Sep 15. No abstract available.

10.

Pharmacokinetics of tazarotene and acitretin in psoriasis.

Heath MS, Sahni DR, Curry ZA, Feldman SR.

Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):919-927. doi: 10.1080/17425255.2018.1515198. Epub 2018 Sep 3. Review.

PMID:
30134735
11.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
12.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.

Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1.

13.

Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial.

Maiti R, Sirka CS, Ashique Rahman MA, Srinivasan A, Parida S, Hota D.

Clin Drug Investig. 2017 Nov;37(11):1083-1091. doi: 10.1007/s40261-017-0568-2.

PMID:
28913735
14.

Ectropion Improvement with Topical Tazarotene in Children with Lamellar Ichthyosis.

Hanson B, Becker L, Hook K, Polcari I, Areaux RG Jr, Maguiness S.

Pediatr Dermatol. 2017 Sep;34(5):584-589. doi: 10.1111/pde.13240. Epub 2017 Aug 17.

PMID:
28815772
15.

D-penicillamine-induced Elastosis Perforans Serpiginosa.

Yao XY, Wen GD, Zhou C, Liu BY, Du J, Chen Z, Zhang JZ.

Chin Med J (Engl). 2017 Aug 20;130(16):2013-2014. doi: 10.4103/0366-6999.211899. No abstract available.

16.

Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration.

Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, Frew J, Gebauer K, Gupta M, Kennedy D, Marshman G, Sullivan J.

Australas J Dermatol. 2018 May;59(2):86-100. doi: 10.1111/ajd.12641. Epub 2017 May 23. Review.

PMID:
28543445
17.
18.

Synthesis and activity of the salicylic acid ester of bakuchiol in psoriasis-surrogate keratinocytes and skin substitutes.

Ma S, Gobis K, Swindell WR, Chaudhuri R, Bojanowski R, Bojanowski K.

Clin Exp Dermatol. 2017 Apr;42(3):251-260. doi: 10.1111/ced.13024. Epub 2017 Jan 4.

19.

The Negative Impact of Selective Activation of Retinoic Acid Receptors on Bone Metabolism and Bone Mechanical Properties in Rats.

Nowak B, Matuszewska A, Filipiak J, Nikodem A, Merwid-Ląd A, Pieśniewska M, Kwiatkowska J, Grotthus B, Szeląg A.

Adv Clin Exp Med. 2016 Mar-Apr;25(2):213-8. doi: 10.17219/acem/41860.

20.

Novel investigational therapies for onychomycosis: an update.

Gupta AK, Studholme C.

Expert Opin Investig Drugs. 2016;25(3):297-305. doi: 10.1517/13543784.2016.1142529. Review.

PMID:
26765142

Supplemental Content

Loading ...
Support Center